TEST:

Aventa FusionPlus Test

Discover how 3D genomics identifies clinically actionable fusions and complex structural rearrangements that traditional methods miss. Learn how the Aventa FusionPlus test can be used to: • Double the detection rate of gene fusions (NTRK, ROS1, EGFR, RET, ALK) in patients who may be eligible for targeted therapies • Increase the detection rate of deleterious HRR mutations in patients who may be eligible for PARP inhibitors • Resolve diagnostic dilemmas in translocation-driven tumors

As an example, in a breast cancer case, a fusion of genomic regions neighboring BRAF and MYC oncogenes on chromosomes 7 and 8 respectively, was missed by the reference method but was successfully detected by the Aventa FusionPlus test.The Aventa FusionPlus test is a highly sensitive, specific, and accurate method for comprehensive cancer genomic profiling. The enhanced understanding of gene fusions and rearrangements positions the test as a valuable tool for clinical decision-making in oncology.

"Aventa™ Genomics, LLC...announced the launch of Aventa FusionPlus, a next-generation sequencing (NGS) test for the detection of gene fusions, translocations, and rearrangements across 361 genes from formalin-fixed, paraffin embedded (FFPE) tumor tissue. Aventa’s testing service is performed in its CLIA-certified laboratory in Orlando, Florida."